RT Journal Article
T1 Higher prevalence of LAP+ (Latency TGFβ-Associated Peptide) T cells at the tissue level in patients with early gastric cancer
A1 Aguinaga Barrilero, Ana
A1 Juárez Martín-Delgado, Ignacio
A1 Vaquero Yuste, Christian
A1 Molina Alejandre, Marta
A1 Gutiérrez Calvo, Alberto
A1 Lasa, Inmaculada
A1 López, Adela
A1 Gómez, Remedios
A1 Molanes López, Elisa M.
A1 Martin Villa, Jose Manuel
AB The presence of cells with regulatory functions in patients with cancer is one of the mechanisms whereby the immune system cannot confront tumor growth. We sought to determine the prevalence of immunoregulatory Tcell subpopulations, expressing the latency TGFβ-associated peptide (LAP), in patients with gastric adenocarcinoma.T cells were enriched from blood or gastric tissue (tumoral, TT or tumor-free, TF) samples from 22 patients, 6 with early (EGC) and 16 with advanced gastric cancer (AGC). CD4, CD8, LAP, FoxP3 and IFN-γ were measured by cytometry.CD8 + LAP + cells were increased at tumoral sites, especially in early stages of the disease, as compared to tumor-free explants (EGC 5.28 % [4.67–6.64]*; AGC 2.90 % [1.37–4.44]; TF 3.14 % [2.33–4.16]; *p < 0.05 vs TF). Likewise, the LAP+/CD8 + LAP- ratio is increased in gastric samples from patients with early disease (EGC 0.38 [0.30–0.45]*, AGC 0.12 [0.07–0.14]; TF 0.12 [0.09–0.31]; *p < 0.05 vs AGC). Disease progression is accompanied by decreased LAP membrane expression and, probably, increased LAP secretion, therefore limiting the response to the tumor.
PB Elsevier
SN 1090-2163
YR 2022
FD 2022-10-28
LK https://hdl.handle.net/20.500.14352/72560
UL https://hdl.handle.net/20.500.14352/72560
LA eng
NO CRUE-CSIC (Acuerdos Transformativos 2022)
NO Instituto de Salud Carlos III (ISCIII)/FEDER
NO Comunidad de Madrid
NO Universidad Complutense de Madrid—Real Colegio Complutense Harvard. Ayuda contratos predoctorales CT18/16
DS Docta Complutense
RD 6 may 2024